| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michael Won. mTOR as a potential treatment target for epilepsy. Future neurology. vol 7. issue 5. 2021-11-10. PMID:23620711. |
some clinical data suggest that mtor inhibitors decrease seizures in tuberous sclerosis complex patients, but controlled trials are lacking and no clinical data on potential anti-epileptogenic actions exist. |
2021-11-10 |
2023-08-12 |
Not clear |
| Cormac McCarthy, Nishant Gupta, Simon R Johnson, Jane J Yu, Francis X McCormac. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. The Lancet. Respiratory medicine. vol 9. issue 11. 2021-11-08. PMID:34461049. |
the invading cell in lam arises from an unknown source and harbours mutations in tuberous sclerosis complex (tsc) genes that result in constitutive activation of the mechanistic target of rapamycin (mtor) pathway, dysregulated cellular proliferation, and a programme of frustrated lymphangiogenesis, culminating in disordered lung remodelling and respiratory failure. |
2021-11-08 |
2023-08-13 |
Not clear |
| Karen Agricola, Gabrielle Stires, Darcy A Krueger, Jamie K Capal, David N Franz, David M Ritte. Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors. Pediatric neurology. vol 120. 2021-11-05. PMID:33962348. |
diabetes in individuals with tuberous sclerosis complex treated with mtor inhibitors. |
2021-11-05 |
2023-08-13 |
Not clear |
| Sophie M Peeters, Yagmur Muftuoglu, Brian Na, David J Daniels, Anthony C Wan. Pediatric Gliomas: Molecular Landscape and Emerging Targets. Neurosurgery clinics of North America. vol 32. issue 2. 2021-10-28. PMID:33781501. |
promising targeted therapies include mtor inhibitors for subependymal giant cell astrocytomas in tuberous sclerosis, braf and mek inhibitors mainly for low-grade gliomas, and mek inhibitors for nf1-deficient braf:kiaa fusion tumors. |
2021-10-28 |
2023-08-13 |
Not clear |
| Ling-Hui Zeng, Nicholas R Rensing, Michael Won. Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway. Molecular and cellular pharmacology. vol 1. issue 3. 2021-10-20. PMID:20419051. |
recent work implicates the mammalian target of rapamycin (mtor) pathway as mediating epileptogenesis in a genetic epilepsy, tuberous sclerosis complex (tsc), and suggests that mtor inhibitors, such as rapamycin, may have antiepileptogenic properties for epilepsy in tsc. |
2021-10-20 |
2023-08-12 |
Not clear |
| Maren Schmiester, Anna Dolnik, Uwe Kornak, Berit Pfitzner, Michael Hummel, Denise Treue, Arndt Hartmann, Abbas Agaimy, Veronika Weyerer, Anja Lekaj, Susanne Brakemeier, Robert Peters, Robert Öllinger, Sven Märdian, Lars Bullinger, Jana Käthe Striefler, Anne Flörcke. TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms. The journal of pathology. Clinical research. vol 7. issue 1. 2021-10-13. PMID:33180365. |
upregulation of mtor signaling due the inactivation of tsc1/2 (tuberous sclerosis 1 and 2) is believed to be a key oncogenic driver in this disease. |
2021-10-13 |
2023-08-13 |
Not clear |
| Till S Zimmer, Anatoly Korotkov, Susan Zwakenberg, Floor E Jansen, Fried J T Zwartkruis, Nicholas R Rensing, Michael Wong, Angelika Mühlebner, Erwin A van Vliet, Eleonora Aronica, James D Mill. Upregulation of the pathogenic transcription factor SPI1/PU.1 in tuberous sclerosis complex and focal cortical dysplasia by oxidative stress. Brain pathology (Zurich, Switzerland). vol 31. issue 5. 2021-10-13. PMID:33786950. |
tuberous sclerosis complex (tsc) is a congenital disorder characterized by cortical malformations and concomitant epilepsy caused by loss-of-function mutations in the mtor suppressors tsc1 or tsc2. |
2021-10-13 |
2023-08-13 |
Not clear |
| Hao Tang, Tong Fang, Meng Ji, Jun-Ping Wang, Le-Le Song, Qiu-Yan Zhang, Jin-Sheng W. UBE2S exerts oncogenic activities in urinary bladder cancer by ubiquitinating TSC1. Biochemical and biophysical research communications. vol 578. 2021-10-11. PMID:34520980. |
furthermore, we discovered that this ube2s-modulated carcinogenic mechanism was in the consequence of directly targeting tuberous sclerosis 1 (tsc1), which is the upstream inhibitor of mtor signaling for ubiquitous degradation. |
2021-10-11 |
2023-08-13 |
Not clear |
| Xin Zhan, Yiran Xie, Liping Sun, Qi Si, Hongkai Shan. Dexamethasone may inhibit placental growth by blocking glucocorticoid receptors via phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin and reactive oxygen species/AMP-activated protein kinase signalling pathways in human placental JEG-3 cells. Reproduction, fertility, and development. vol 33. issue 12. 2021-10-08. PMID:34399087. |
treatment of jeg-3 cells with grα sirna, ly294002, xo/hx or rapamycin inhibited phosphorylation of phosphatidylinositol 3-kinase (pi3k), akt, glycogen synthase kinase 3 and mammalian target of rapamycin (mtor) and induced the phosphorylation of amp-activated protein kinase (ampk) and tuberous sclerosis complex 2. |
2021-10-08 |
2023-08-13 |
human |
| Anna Caliò, Matteo Brunelli, Diego Segala, Giuseppe Zamboni, Franco Bonetti, Maurizio Pea, Guido Martignon. Angiomyolipoma of the kidney: from simple hamartoma to complex tumour. Pathology. vol 53. issue 1. 2021-10-04. PMID:33131798. |
the activation of the mtor pathway due to genetic alterations of tuberous sclerosis complex in tsc1 or tsc2 genes in angiomyolipoma has also been reported as well as the subsequent therapeutic implications. |
2021-10-04 |
2023-08-13 |
Not clear |
| Qianwei Ye, Sunbin Ling, Guangjiang Jiang, Qiaonan Shan, Shengjun Xu, Qifan Zhan, Yifeng Wu, Yuchen Liu, Shusen Zheng, Xiao X. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. vol 47. issue 10. 2021-09-17. PMID:33902956. |
sirolimus is a typical mammalian target of rapamycin (mtor) inhibitor, and tuberous sclerosis 1-tuberous sclerosis 2 complex (tsc1/tsc2) is an important negative effector in the mtor pathway. |
2021-09-17 |
2023-08-13 |
Not clear |
| b' Francesco Bruno, Alessia Pellerino, Luca Bertero, Riccardo Soffietti, Roberta Rud\\xc3\\xa. Targeted Therapies in Rare Brain Tumours. International journal of molecular sciences. vol 22. issue 15. 2021-09-09. PMID:34360713.' |
we will discuss options such as targeting the mechanistic target of rapamycin (mtor) pathway in subependymal giant cells astrocytomas (segas) of tuberous sclerosis and braf v600e mutation in rare glial (pleomorphic xanthoastrocytomas) or glioneuronal (gangliogliomas) tumours, which are a model of how specific molecular treatments can also favourably impact neurological symptoms (such as seizures) and quality of life. |
2021-09-09 |
2023-08-13 |
Not clear |
| Correction for Tee et al., Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proceedings of the National Academy of Sciences of the United States of America. vol 118. issue 33. 2021-08-31. PMID:34373336. |
correction for tee et al., tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mtor)-mediated downstream signaling. |
2021-08-31 |
2023-08-13 |
Not clear |
| Wiebke Theilmann, Birthe Gericke, Alina Schidlitzki, Syed Muhammad Muneeb Anjum, Saskia Borsdorf, Timon Harries, Steven L Roberds, Dean J Aguiar, Daniela Brunner, Steven C Leiser, Dekun Song, Doriano Fabbro, Petra Hillmann, Matthias P Wymann, Wolfgang Lösche. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology. vol 180. 2021-08-27. PMID:32890589. |
the rapamycin derivative ("rapalog") everolimus, which allosterically inhibits the mtor pathway, is approved for the treatment of partial epilepsy with spontaneous recurrent seizures (srs) in individuals with tuberous sclerosis complex (tsc). |
2021-08-27 |
2023-08-13 |
mouse |
| Tomas Petrasek, Iveta Vojtechova, Ondrej Klovrza, Klara Tuckova, Cestmir Vejmola, Jakub Rak, Anna Sulakova, Daniel Kaping, Nadine Bernhardt, Petrus J de Vries, Jakub Otahal, Robert Walterei. mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus. Journal of neurodevelopmental disorders. vol 13. issue 1. 2021-08-26. PMID:33863288. |
tuberous sclerosis complex (tsc), a multi-system genetic disorder often associated with autism spectrum disorder (asd), is caused by mutations of tsc1 or tsc2, which lead to constitutive overactivation of mammalian target of rapamycin (mtor). |
2021-08-26 |
2023-08-13 |
Not clear |
| Caroline Raab, Leah A Gilligan, Andrew T Trout, Darcy A Krueger, David N Franz, Bin Zhang, Alexander J Towbi. mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI. Radiology. Imaging cancer. vol 2. issue 5. 2021-08-25. PMID:33778734. |
mtor inhibitor therapy for tuberous sclerosis complex: longitudinal study of muscle mass determined by abdominal cross-sectional imaging with ct and mri. |
2021-08-25 |
2023-08-13 |
Not clear |
| Caroline Raab, Leah A Gilligan, Andrew T Trout, Darcy A Krueger, David N Franz, Bin Zhang, Alexander J Towbi. mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI. Radiology. Imaging cancer. vol 2. issue 5. 2021-08-25. PMID:33778734. |
to determine the effect of chronic mammalian target of rapamycin (mtor) inhibition on skeletal muscle mass in patients with tuberous sclerosis complex (tsc). |
2021-08-25 |
2023-08-13 |
Not clear |
| Sean R Williamson, Leonardo Cardili, Lisa J Whiteley, Jessica Sanchez, Olena Ki. Sclerosing TSC1 mutated renal cell carcinoma: An unusual pattern mimicking MITF family translocation renal cell carcinoma. Genes, chromosomes & cancer. vol 59. issue 10. 2021-08-18. PMID:32418252. |
the tuberous sclerosis genes and mtor are increasingly being found to have important roles in novel subtypes of renal cancer, particularly emerging entities eosinophilic solid and cystic renal cell carcinoma (rcc) and high-grade oncocytic renal tumor (hot)/rcc with eosinophilic and vacuolated cytoplasm. |
2021-08-18 |
2023-08-13 |
Not clear |
| Melissa Y Tjota, Pankhuri Wanjari, Jeremy Segal, Tatjana Anti. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study. Human pathology. vol 115. 2021-08-16. PMID:33352195. |
we previously demonstrated that a subset of eosinophilic renal tumors with heterogeneous morphology and immunohistochemical (ihc) staining harbored pathogenic mutations in tuberous sclerosis complex (tsc) or mammalian target of rapamycin (mtor) as the primary defining mutation. |
2021-08-16 |
2023-08-13 |
Not clear |
| Justyna Jakubowska, Bartłomiej Pawlik, Krystyna Wyka, Małgorzata Stolarska, Katarzyna Kotulska, Sergiusz Jóźwiak, Wojciech Młynarski, Joanna Trelińsk. New Insights into Red Blood Cell Microcytosis upon mTOR Inhibitor Administration. International journal of molecular sciences. vol 22. issue 13. 2021-07-26. PMID:34202704. |
the aim of this study was to evaluate the effect of everolimus, a mammalian target of rapamycin (mtor) inhibitor, on red blood cell parameters in the context of iron homeostasis in patients with tuberous sclerosis complex (tsc) and evaluate its effect on cell size in vitro. |
2021-07-26 |
2023-08-13 |
human |